文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

放射性诊疗核医学的经济性评估:系统综述

Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.
PubMed 文献 · J Nucl Med · 2026-08-03

Radiotheranostic therapy (RTT) is an emerging form of personalized cancer care that combines radiopharmaceutical imaging and radiopharmaceutical therapy (RPT). Although promising clinically, the value for money of RTT remains uncertain.…

要点

  • 放射性药物成像的ICER为21,350至146,526美元/QALY,放射性药物治疗为66,761至397,342美元/QALY。
  • 80%的成像研究评估68Ga,所有RPT研究评估177Lu。
  • HTA机构指出证据、对照选择和模型假设的不确定性,以及缺乏对供应、劳动力和基础设施约束的考虑。

核心结论

  • RTT的经济学评估存在显著异质性和方法学缺陷,导致其经济性不确定。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索7个电子数据库及HTA机构数据库,覆盖2015至2025年发表的文献,最终检索于2025年9月进行。

主要发现

  • 放射性药物成像的ICER范围为21,350至146,526美元/QALY。
  • 放射性药物治疗的ICER范围为66,761至397,342美元/QALY。
  • 80%的放射性药物成像研究评估68Ga,所有RPT研究评估177Lu。
  • 半数基于模型的经济学评估聚焦前列腺癌,其余为神经内分泌肿瘤。

关键数值与推荐

  • 方法学质量采用CHEQUE框架评估,报告质量采用CHEERS清单评估。

临床怎么用

  • 临床决策需考虑RTT经济性证据的异质性和不确定性,HTA框架应整合完整诊疗路径并考虑系统层面约束和公平性。

局限性

  • 纳入研究的方法学异质性大,HTA机构指出证据、对照选择和模型假设存在不确定性,且缺乏对供应、劳动力和基础设施约束等现实因素的考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiotheranostic therapy (RTT) is an emerging form of personalized cancer care that combines radiopharmaceutical imaging and radiopharmaceutical therapy (RPT). Although promising clinically, the value for money of RTT remains uncertain. The objective of this study is to review the cost-effectiveness evidence of RTT in cancer and critically appraise the methodologies utilized in conducting the included economic evaluations. Methods: A systematic literature review was conducted in accordance with the PRISMA guidelines. A comprehensive search strategy encompassing key search terms related to economic evaluations of RTT in oncology was performed across 7 electronic databases (CINAHL, Econlit, Embase, PubMed, Scopus, Web of Science, and International HTA database), as well as databases of health technology assessment (HTA) agencies (Canada's Drug Agency, Medical Services Advisory Committee, and the National Institute for Health and Care Excellence). The final search was conducted in September 2025 and covered published articles, reports, and HTA appraisals from 2015 to 2025. Methodologic quality was assessed using the CHEQUE framework, whereas reporting quality was evaluated using the CHEERS checklist. Results: Sixteen articles or reports and 9 HTA appraisals were included. Among the radiopharmaceutical imaging studies, 80% evaluated 68Ga whereas all RPT studies assessed 177Lu. Half of the model-based economic evaluations focused on prostate cancer and the rest on neuroendocrine tumors. The modeling approach in the evaluations varied, and the reported incremental cost-effectiveness ratio ranged from $21,350 to $146,526/quality-adjusted life-year for radiopharmaceutical imaging and from $66,761 to $397,342/quality-adjusted life-year for RPTs. HTA agencies identified uncertainties in evidence, comparator choice, and model assumptions and highlighted the absence of real-world considerations such as supply, workforce, and infrastructure constraints. Conclusion: This review identifies substantial heterogeneity and methodologic gaps in the economic evaluation of RTTs, contributing to uncertainty around their value for money. These findings underscore the need for fit-for-purpose HTA frameworks that integrate the full theranostic pathway and address system-level constraints and equity considerations.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang Y, Wood JL, Thurecht KJ, et al. Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review. J Nucl Med. 2026. PMID: 42167807. doi:10.2967/jnumed.125.271469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。